Oncology

Posted 12 months ago by Wales Gene Park

LUCID: A study looking at breath samples to find out if these can help to diagnose lung cancer This study is for people who have been referred for tests because they might have lung cancer. Researchers would like to develop a test to pick up lung cancer at an earlier stage. This way, more people could have a chance of successful treatment. Research has shown that cells inside the body make substances that end up in the lungs. These substances are then breathed out. Researchers think that the substances may be different if a person has lung cancer. This study will look at biomarkers in a person’s breath. Biomarkers are substances in the body that can be measured. Some biomarkers can help doctors to diagnose cancer, predict whether a treatment will work and show whether treatment is working. The aims of this study are to learn more about the different biomarkers in breath...

 Small cell lung cancer /  England

Posted 12 months ago by Wales Gene Park

CHEMORES: A study to understand more about why chemotherapy to treat lung cancer can stop working This study will look for changes in blood and tissue samples before and after treatment for lung cancer, to try to find out how cancer cells stop themselves being harmed by treatment. Doctors may use surgery, radiotherapy, chemotherapy or another type of drug that targets lung cancer to treat this disease. Your treatment will depend on your type and stage of lung cancer. If you have non small cell lung cancer, you may have a combination of these. If you have small cell lung cancer, you would usually have chemotherapy. We know from research that cancer cells can become 'resistant’ to treatment. In lung cancer for example, cancer cells can sometimes reduce the concentration of the drug inside them, and repair DNA damage. And, develop changes in the genes in cancer cells that prevent the treatment from working. Understanding why resistance happens will help develop improved...

 Small cell lung cancer /  Manchester

Posted 12 months ago by Wales Gene Park

PROGENOM: A study to understand more about an eye cancer called uveal melanoma This study is gathering information from blood and tissue samples, which may help to predict outlook (prognosis) and identify new treatments for people with uveal melanoma.

 uveal melanoma /  Liverpool

Posted 12 months ago by Wales Gene Park

This study is looking at blood samples to find out more about the genetic causes of kidney cancer. There are many risk factors associated with developing renal cell carcinoma (RCC). This is the most common form of kidney cancer. There are some faulty genes and inherited conditions that increase risk. This study is looking at people who may have an inherited genetic fault or medical condition that increases their risk of developing RCC. The aim of the study is to find out more about the genetic causes of RCC, and more about how gene faults may increase risk.

 Rare Kidney Cancers /  England

Posted 12 months ago by Wales Gene Park

PETReA: A study to find out whether a PET-CT scan can help to tell who needs to have rituximab after the initial treatment for lymphoma. Follicular Lymphoma is a type of non Hodgkin lymphoma (NHL). Doctors usually put NHL into 2 groups, depending on how likely they are to grow and spread. The 2 groups are low grade and high grade NHL. Follicular lymphoma is a type of low grade NHL. For follicular lymphoma, you usually have treatment with a combination of cancer drugs. You might have one of the following: R-CHOP R-CVP bendamustine and rituximab (BR) This is called the induction treatment. After the induction treatment, you might have rituximab (R) alone. This is the maintenance phase. But having more treatment with rituximab doesn’t help everyone with follicular lymphoma. Doctors would like to know who needs to have rituximab after their initial treatment (induction). In this study, they are looking...

 Non-Hodgkin lymphoma /  Wales Wide

Posted 12 months ago by Wales Gene Park

AUTO4-TL1: A trial of CAR T-cell for people with T cell lymphoma Researchers are looking at new ways to help people with relapsed or refractory T cell lymphoma. In this trial, they are looking at a new treatment called CAR T-cell. CAR T-cell treatment uses the T cells from your immune system. These cells are good at helping us fight infections, but they aren’t so good at recognising lymphoma cells. With this treatment, doctors collect your T cells and change them in the laboratory so that they recognise and attack the lymphoma cells that have the TRBC1 protein. These altered T cells are called AUTO4. This trial is in 2 parts. In part 1 doctors are looking for the best dose of AUTO4. This part is called dose escalation. In part 2, they will collect information about how well the treatment works. This is the dose expansion part.

 Non-Hodgkin lymphoma /  England

Posted 1 year ago by Wales Gene Park

This trial is looking at a new treatment using anti-GD2 T-cells. The researchers are taking immune cells from the blood and changing them so they can attack the cancer cells. Cancer Research UK is supporting this trial. The aims of the trial are to find out: if they can make anti-GD2 T-cells in the laboratory and if it is safe to give to people about any side effects and the best way to treat them whether giving chemotherapy first, improves how long the anti-GD2 T-cells survive and helps to increase their number how well and for how long the anti-GD2 T-cells survive inside the body whether anti-GD2 T-cells can shrink the neuroblastoma

 Neuroblastoma /  London

Posted 1 year ago by Wales Gene Park

This trial is looking at a new vaccine made by altering people’s own donated leukaemia cells and injecting them back to trigger their immune system. You have the vaccine with the standard treatment of having white blood cells through a drip into a vein.

 Acute myeloid leukaemia /  London

Posted 1 year ago by Wales Gene Park

A trial of nivolumab for Hodgkin lymphoma This trial is looking at whether nivolumab can improve treatment before a stem cell transplant for people with Hodgkin lymphoma.

 Classic Hodgkin lymphoma /  England

Posted 1 year ago by Wales Gene Park

A trial looking at ibrutinib and standard treatment for children and young adults with B cell non-Hodgkin lymphoma This trial is for children and teenagers with a type of acute lymphoblastic leukaemia called pre cursor B cell ALL that has come back after initial treatment.

 Paediatric Cancers /  England

Posted 1 year ago by Wales Gene Park

A study looking at pembrolizumab for children and teenagers with a solid tumour or lymphoma This study is looking at a drug called pembrolizumab for children and teenagers who have advanced melanoma or certain other types of solid tumour or lymphoma. This study is for children who are at least 6 months old but haven’t yet reached their 18th birthday. We use the term ‘you’ in this summary, but if you are a parent, we are referring to your child.

 Haematological Cancer /  London

Posted 1 year ago by Wales Gene Park

This study is looking at scans, blood tests and lung fluid tests to improve diagnosis for people with fluid in the lung lining (pleural effusion), or thickening of the lung lining.

 mesothelioma /  Bristol

Posted 1 year ago by Wales Gene Park

A study looking at functional imaging to help diagnose and treat children and young people with solid tumours This study is looking at functional imaging, using a range of scanning techniques to help diagnose, treat and understand more about solid tumours in children and young people. This study is for children and young people up to their 25th birthday at diagnosis.

 Paediatric Cancers /  England

Posted 1 year ago by Wales Gene Park

ATLANTIS: A trial of more treatment after chemotherapy for advanced urinary tract cancer  

 Urological Cancers /  Cardiff

Posted 1 year ago by Wales Gene Park

The aims of this study are to Find out if surgery of the prostate, bladder, penis and kidney causes changes to biomarkers in the body See if there is a link between changes in these biomarkers and complications after surgery See if there is a link between changes in these biomarkers and the cancer coming back

 Urological Cancers /  Wales Wide

Posted 1 year ago by Wales Gene Park

IMPORT: A study looking at improving treatment for children with kidney cancer This study will collect information about children diagnosed with kidney cancer (renal cancer) such as Wilms’ tumour, to help with decisions about treatment in the future.

 Paediatric Cancers /  Cardiff

Posted 1 year ago by Wales Gene Park

Researchers are looking at new ways to treat cancer. An area that they are looking at is personalised therapy. Cancer cells have changes in their genes (DNA) that make them different from normal cells. These changes mean that they behave differently. It can also make one person’s cancer different to another’s. A technique called genomic profiling can scan the genes of the cancer and identify those changes. Doctors hope they can match a treatment to your individual cancer. The main aim of this trial is to find out whether personalised therapy is better than chemotherapy for people with CUP.

 Rare Cancers (non-specific) /  Cardiff

Posted 1 year ago by Wales Gene Park

The UKALL14 trial is looking at different treatments for ALL. The team would now like to do a sub study to find out more about the genes of the leukaemic cells. They also want to find out more about whether they can predict how well treatment will work based on these changes. In this study you have the standard chemotherapy treatment for ALL at your hospital. The study team will ask for small amount of your bone marrow sample  that is taken before starting your treatment. They are looking for a substance (biomarker ) in the sample they can use to follow how well your leukaemia responds to treatment. They are also looking for any gene changes in the cells of your leukaemia.

 Acute lymphoblastic leukaemia (ALL) /  Wales Wide

Posted 1 year ago by Wales Gene Park

OPTIMA: A trial looking at a test to predict who might benefit from chemotherapy for breast cancer Chemotherapy and hormone treatment are currently offered to many people as part of their breast cancer treatment. This is to reduce the chance of the cancer coming back. Chemotherapy is given as an injection, usually every three weeks over a few months. Hormone therapy is a daily tablet taken for five to ten years. Younger women may also have a monthly injection to stop menstrual periods. Recently however it has been argued that chemotherapy may have little effect on the subtype of breast cancer that is broadly identified as being hormonally responsive without HER2 gene amplification/HER2 protein overexpression and with a low or intermediate grade. Recent research indicates that some people with this subtype of breast cancer may not benefit from chemotherapy, and would do just as well with hormone treatment alone. The...

 Breast Cancer /  Wales Wide

Posted 1 year ago by Wales Gene Park

Looking at circulating tumour cells in the blood will help researchers learn more about why treatment works better in some women than others and about how cancer spreads. The aims of this study are to find out •If cancer cells in the blood can be easily detected and counted •More about breast cancer, to help improve treatment in the future •More about how breast cancer spreads You will not have any direct benefit from taking part in this study, and it is unlikely to change your treatment plan in any way. But the results of the study will be used to help women in the future.

 Hereditary breast cancer /  London

Posted 1 year ago by Wales Gene Park

FOCUS4: A trial looking at different treatments for different types of bowel cancer Not all bowel cancers are the same and tests can be done on tumour samples from patients with bowel cancer that may help select the best treatment for that individual patient. There are a number of new cancer drugs that may be more beneficial in one type of bowel cancer than another. The FOCUS4 trial programme aims to recruit over 1500 patients at centres across the UK to evaluate how well these new cancer drugs work in different types of bowel cancer. Patients diagnosed with bowel cancer which is not removable by surgery or has spread to elsewhere in their body will be invited to join this programme of trials. Patients who decide to join will be started on a course of chemotherapy (a form of drug treatment aimed to kill the cancer cells) for up to...

 Rare Bowel Cancers /  Cardiff University

Posted 1 year ago by Wales Gene Park

CORGI 2: A study to find genes that might increase or reduce the risk of bowel cancer Colorectal cancer (CRC) remains an important cause of morbidity and mortality. Identifying those at higher risk is important in targeting preventive measures, such as screening colonoscopy, to those most likely to benefit. Much of the risk of CRC and its precursor lesions (mostly polyps) is genetic, but a great deal of the heritability of CRC remains unexplained. Some of the remaining genetic risk probably results from rare genes with large effects, some from uncommon genetic variants with moderate effects and some from common differences with modest or very modest effects. The sub-division between these categories is extremely difficult to predict in advance of successful searches for these genes. The principal aim of this study is to identify additional susceptibility genes for CRC and cancers genetically related to CRC, such as endometrial cancer. This...

 Rare Bowel Cancers /  Birmingham

Posted 1 year ago by Wales Gene Park

ALL-RIC:A trial comparing treatments for acute lymphoblastic leukaemia Doctors are looking for new ways to treat people with acute lymphoblastic leukaemia (ALL) to stop the leukaemia coming back. In this trial, they are comparing a usual treatment with a new combination of treatment. The usual (standard) treatment in this trial is a combination of drugs called FMA. It includes: •fludarabine – a chemotherapy drug •melphalan – a chemotherapy drug •alemtuzumab – a targeted drug The new combination of treatment includes: •cyclophosphamide – a chemotherapy drug •alemtuzumab – a targeted drug •radiotherapy to the whole body (total body irradiation or TBI) Everyone then goes on to have a stem cell transplant with stem cells from another person (an allogeneic stem cell transplant). The chemotherapy and radiotherapy in this trial are low intensity. This is to reduce the possible complications of a transplant. We know from early research that the new combination...

 Chronic lymphocytic leukaemia /  England

Posted 1 year ago by Wales Gene Park

MICROBIOME- A study of MRx0518 before surgery for solid tumours This study is looking at a new treatment called MRx0518 for solid tumours.

 Rare Cancers (non-specific) /  London

Posted 1 year ago by Wales Gene Park

DIAMOND: A study looking at biomarkers in prostate, kidney, bladder and testicular cancer Some people have biomarkers that make them more vulnerable to develop certain types of cancer. In this study, doctors want to look for these biomarkers. They hope this information will help them: •learn more about the causes of cancer •develop better tests and treatments Everyone taking part gives blood, urine, poo and breath samples. Doctors may also ask for a tissue sample if you had, or are going to have, surgery. The main aim of this study is to look for biomarkers that might play a role in prostate, kidney, bladder and testicular cancer. Researchers are also looking for men who are going to have a biopsy to find out whether they have prostate cancer. This is part of a sub study called PRIM. Everyone taking part in the PRIM sub study has a blood test called...

 Prostate Cancer /  Bristol

Posted 1 year ago by Wales Gene Park

This trial is for people whose acute myeloid leukaemia (AML) has come back or continued to grow following their first or second treatment.

 Acute myeloid leukaemia /  Cardiff

Posted 1 year ago by Wales Gene Park

ABC-07: A trial looking at stereotactic body radiotherapy and chemotherapy for people with locally advanced bile duct cancer The purpose of the ABC-07 trial is examine whether adding radiotherapy called Stereotactic Body Radiotherapy (SBRT) to chemotherapy will improve the outcome for patients with locally advanced biliary tract cancer that are unfit for surgery. All patients will receive 6 cycles of chemotherapy and then they will receive either 5 fractions of SBRT or 2 more cycles of chemotherapy depending on which treatment they are randomised to. Initially we plan to undertake a feasibility phase to see if it is possible to recruit patients into the trial and then we will continue with the randomised phase II study. Patients recruited during this feasibility stage will be included in the analysis of the full randomised phase II study.

 Fibrillary astrocytoma /  Cardiff

Posted 1 year ago by Wales Gene Park

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(Biomede) Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

Many cancers have hijacked growth factor receptors and or downstream signalling components through mutations that render the pathway constantly active and so drive cancer cells division. Over the last decade, drugs have been introduced that simultaneously inhibit multiple growth factor pathways (such as tyrosine kinase receptor inhibitors), single pathways (vascular endothelial growth factor receptor, transforming growth factor beta receptor, epidermal growth factor receptor and hedgehog pathway antagonists), mutated targets (B-Raf inhibitors), and downstream signalling targets (MEK inhibitors). While malignancies in patients often demonstrate an initial response to these drugs, cancer recurrence is frequently observed. My group over the last five years has defined cancer stem cells (CaSC) in the two commonest skin cancers, using internationally agreed assays. We have shown in high impact scientific publications that basal cell carcinoma (BCC) CaSC are resistant to both conventional chemotherapy and the recently approved growth factor inhibitor vismodegib. Microarray analysis of treated and...

 Oncology /  Cardiff University

Posted 1 year ago by Wales Gene Park

 A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumours.  

 Oncology /  London

Posted 1 year ago by Wales Gene Park

A trial looking at treatment for children and young adults with an ependymoma This trial is looking at chemotherapy and extra doses of radiotherapy after surgery to treat ependymoma. It is open to children and young adults with an ependymoma that hasn’t been completely removed by surgery. Cancer Research UK supports this trial. There are 2 parts to this trial. In the 1st part the trial committee looks at the results of your tests and scans. The 2nd part is looking at treatment pathways. There are 3 treatment pathways in this trial. This information is about pathway 2. We have information on pathway 1 and pathway 3. The aims of this trial are to find How well vincristine, etoposide, cyclophosphamide and high dose methotrexate works to treat ependymoma How safe the combination is What are the side effects of this combination How safe it is give 2 more doses of...

 Ependymoma (on the brain) /  England

Posted 1 year ago by Wales Gene Park

This trial is looking at treating ependymoma with chemotherapy after surgery and radiotherapy. It is open to children and young adults whose ependymoma has been completely removed by surgery. Cancer Research UK supports this trial. There are 2 parts to this trial. In the 1st part the trial committee looks at the results of your tests and scans. The 2nd part is looking at treatment pathways. There are 3 treatment pathways in this trial. This information is about pathway 1. We also have information on pathway 2 and pathway 3. The aims of this trial are to find out how well chemotherapy after surgery and radiotherapy works to stop ependymoma coming back about the side effects of having chemotherapy after surgery and radiotherapy how safe it is to give chemotherapy after surgery and radiotherapy

 Ependymoma (on the brain) /  England

Posted 1 year ago by Wales Gene Park

A trial looking at lenvatinib and pembrolizumab for people with advanced solid tumours (LEAP-005) This trial is for people with one of the following solid tumours : breast cancer whose cells don’t have receptors for the protein Her2 and the hormones oestrogen and progesterone (triple negative breast cancer) ovarian cancer stomach cancer bowel cancer a type of brain tumour called glioblastoma multiforme (GBM) bile duct cancer gallbladder cancer It is for people whose cancer continued to grow or spread to other parts of the body despite treatment (advanced solid tumours). The main aims of this trial are to: find out how well lenvatinib and pembrolizumab work as a treatment for advanced solid tumours learn more about the side effects

 Rare Cancers (non-specific) /  London

Posted 1 year ago by Wales Gene Park

A study looking at improving treatment for children and young people with medulloblastoma (PNET5 MB) The PNET 5 study has been designed for children and young people aged from 3 yrs to 22 yrs with standard risk medulloblastoma who have undergone surgery to remove the primary tumour. The presence of biological markers of the WNT medulloblastoma disease subgroup (mutation of the beta-catenin gene, or presence of the beta-catenin protein and loss of chromosome 6) and aged < 16 defines the patient as Low Risk biological profile. The presence of the WNT markers and aged 16 and over, or the absence of the WNT markers defines the patient as Standard Risk biological profile. Low risk group patients will receive reduced doses of radiotherapy (compared to previous study PNET 4) to the brain and spine every day for 10 days, together with boost doses to the primary tumour for a further 20...

 Classic medulloblastoma /  Cardiff

Posted 1 year ago by Wales Gene Park

Ependymoma is a type of brain tumour that mostly affects children and young people. We use the term ‘you’ in this summary, but if you are a parent, we are referring to your child. Doctors usually treat ependymoma by removing it with surgery. After surgery if you can’t have radiotherapy you have chemotherapy instead. In this pathway researchers want to find out if adding a drug called valproic acid to chemotherapy improves treatment. Valproic acid is a drug that blocks substances (enzymes ) in the body called histone deacetylases (pronounced dee-as-et-isle-azes). Cells need these to grow and divide. Blocking them may stop cancer growing. Drugs that block these enzymes are called histone deacetylase inhibitors or HDAC inhibitors. We know from research that valproic acid can help people with other types of brain tumours. The aims of this pathway are to find how well chemotherapy with valproic acid works for young...

 Ependymoma (on the brain) /  Cardiff

Posted 1 year ago by Wales Gene Park

This trial is looking at treating ependymoma with chemotherapy after surgery and radiotherapy. It is open to children and young adults whose ependymoma has been completely removed by surgery. Cancer Research UK supports this trial. There are 2 parts to this trial. In the 1st part the trial committee looks at the results of your tests and scans. The 2nd part is looking at treatment pathways. There are 3 treatment pathways in this trial. This information is about pathway 1. We also have information on pathway 2 and pathway 3.

 Ependymoma (on the brain) /  Cardiff

Posted 1 year ago by Wales Gene Park

This trial is looking at adding valproic acid to chemotherapy after surgery to treat ependymoma. It is open to children younger than 1 year old and those with an ependymoma who can’t have radiotherapy after surgery to remove their tumour. Cancer Research UK supports this trial. There are 2 parts to this trial. In the 1st part the trial committee looks at the results of your tests and scans. The 2nd part is looking at treatment pathways. There are 3 treatment pathways in this trial. This information is about pathway 3. We have information on pathway 1 and pathway 2.

 Ependymoma (on the brain) /  England

Posted 1 year ago by Wales Gene Park

Some gliomas have a change (mutation ) in the BRAF gene called BRAF V600. The BRAF gene makes a protein that affects how cancers grow and divide. Dabrafenib and trametinib are targeted drugs. They work by blocking the action of the BRAF protein so possibly stopping the cancer growing or spreading. We know that the combination of dabrafenib and trametinib works for other cancers that have the BRAF V600 change. Researchers think it could help children and young people whose glioma has the BRAF V600 change. In this trial everyone who has a fast growing glioma will have dabrafenib and trametinib. Everyone who has a slow growing glioma will have either: dabrafenib and trametinib or carboplatin and vincristine (standard treatment ) The aims of this trial are to find: how well dabrafenib and trametinib works for children and young people with a glioma how dabrafenib and trametinib works in the...

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

A trial of ipilimumab and temozolomide for people with glioblastoma Glioblastoma is one of the most common types of brain tumours in adults. The usual treatment for people with a newly diagnosed glioblastoma is: surgery to remove some or all of the tumour then 6 weeks of radiotherapy with temozolomide (this is called chemoradiotherapy) then temozolomide alone for up to 6 months (this is the adjuvant treatment) But glioblastomas can come back or continue to grow despite the usual treatment. In this trial, doctors want to find out whether ipilimumab can help to stop glioblastomas from coming back. Ipilimumab (also called by its brand name Yervoy) is a type of targeted drug called a monoclonal antibody. It works by stimulating certain immune cells called T-cells to find and attack the cancer. Ipilimumab is already a possible treatment for people with advanced melanoma. Everyone taking part in this trial has surgery...

 Glioblastoma /  London

Posted 1 year ago by Wales Gene Park

A study looking at blood and tissue samples to learn more about advanced cancer (PEACE) The purpose of the PEACE study is to increase our understanding of the changes that occur in each patient’s cancer by looking at tumour samples taken from patients who have recently died. Our research group is particularly interested in 'intratumour heterogeneity', which tells us that in different parts of the same tumour there can be different gene abnormalities that can interact and dictate how a tumour behaves and therefore how a cancer can progress. This study aims to (1) understand how cancers grow and spread, (2) identify gene abnormalities in different types of cancer, (3) identify markers within tumours that can predict whether a patient will respond to a particular anti-cancer therapy, (4) determine whether a single tissue sample is representative of the entire tumour, or whether multiple samples are required, (5) study the reasons...

 Oncology /  London

Posted 1 year ago by Wales Gene Park

A trial of targeted cancer therapies for children and young people with a brain tumour (BIOMEDE) Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

 Diffuse intrinsic pontine glioma /  London

Posted 1 year ago by Wales Gene Park

Conditions where lymphocytes have become cancerous are called lymphoproliferative disorders and include Chronic lymphocytic leukaemia (CLL) Mantle cell lymphoma Follicular lymphoma Hairy cell leukaemia Splenic lymphoma with villous lymphocytes Doctors want to find out more about these cancerous cells. In this study you will give samples of blood and any extra bone marrow or tissue you may have removed during routine procedures. You will also give a sample of spit (saliva). Researchers will look at both abnormal and normal cells in these samples. They will look for genes, including a particular gene called the ‘immunoglobulin gene’ that help the cancer cell to survive. And, for other gene and chromosome changes that may in future help them predict the outcome of these diseases. The aim of this study is to understand more about how changes to certain genes, proteins and sugars could affect how these diseases develop. This may help develop...

 Classic hairy cell leukemia /  Southampton

Posted 1 year ago by Wales Gene Park

To assess brain tumours doctors can use scans such as an MRI scan. The MRI scan is good at showing where the tumour is and how big it is. But it can’t show other features of the tumour such as how fast it is growing. The researchers want to combine the MRI scan with another scan called a PET scan. They think that this combination might be better at showing these other features of the brain tumour. This information would be helpful when planning further tests or treatments. The main aim of this study is to see if the combination of an MRI scan and PET scan is better at giving more detailed information about a brain tumour than an MRI scan only.

 Diffuse intrinsic pontine glioma /  Cambridge

Posted 1 year ago by Wales Gene Park

Most tumours that start in the pituitary gland are adenomas which are non cancerous (benign). Some pituitary tumours make extra hormones that can cause symptoms. They are sometimes called neuroendocrine tumours. Very rarely, several members of the same family have a pituitary gland tumour. We know from research that there can be a gene that is abnormal in some of these families. Researchers want to study this and other genes to understand more about how these tumours develop. In this study, they will take blood samples from people who have a pituitary gland tumour, and from other family members. The aim of the study is to identify genes that play a part in the development of pituitary gland tumours. Please note - you won’t get any direct benefit from taking part in this study, nor will it affect any treatment you have. But may it help people in the future.

 Pituitary carcinoma /  London

Posted 1 year ago by Wales Gene Park

 A trial looking at higher doses of chemoradiotherapy for people with locally advanced anal cancer (PLATO ACT5) Anal cancer is rare, but its incidence is rising rapidly. Approximately 1000 cases are diagnosed each year in the UK. Standard treatment usually involves a combination of chemotherapy and radiotherapy (chemoradiotherapy (CRT)). Often the same radiotherapy dose is given regardless of disease stage. Recent improvements in radiotherapy means altered doses can now be given to the tumour whilst sparing normal tissues. PLATO is an integrated protocol, comprising 3 separate trials (ACT3, ACT4 and ACT5) which aims to optimise radiotherapy dose for low-, intermediate- and high-risk disease. ACT5: a seamless randomised pilot, phase II and phase III trial that compares standard-dose CRT (53.2Gy in 28 fractions) with two higher doses of CRT (58.8Gy and 61.6Gy, both in 28 fractions), in patients with locally advanced anal cancer, to see if giving a higher dose of...

 Juvenile Anal Cancer /  Leeds

Posted 1 year ago by Wales Gene Park

Doctors can use surgery to remove: prostate cancer bladder cancer penile cancer kidney cancer Doctors think that one way to monitor patients more closely when they have surgery would be to use biomarkers. A biomarker is a substance in the body that can be measured. In this study, the researchers will look at people’s blood and urine samples before and after surgery to measure certain biomarkers. The aims of this study are to Find out if surgery of the prostate, bladder, penis and kidney causes changes to biomarkers in the body See if there is a link between changes in these biomarkers and complications after surgery See if there is a link between changes in these biomarkers and the cancer coming back You will not directly benefit from taking part in this study. If the researchers find that biomarkers are useful, it could help to improve the care and treatment...

 Penile Cancer /  Wales Wide

Posted 1 year ago by Wales Gene Park

We will undertake a prospective study of adult MAP patients with confirmed bi-allelic mutations across collaborating European centres. Data from upper GI surveillance procedures including endoscopy and histopathology findings will be collated as an ongoing process by the Institute of Medical Genetics, Cardiff, UK where it will entered into a database and stored safely. We will also collect prospectively data on other incident cancers diagnosed in these patients. All causes of death and all dates of death will be recorded. Recruitment of patients from the European centres and consent will be obtained using local procedures, and ethical approval will be obtained in each country. As MAP is a rare disorder, and the interval between surveillance procedures may be as much as 5 years, this study is planned to take place over 20 years.

 MUTYH-Associated Adenomatous Polyposis (MAP) /  Cardiff University

Posted 1 year ago by Wales Gene Park

HumGenDisMolecular pathology of human genetic disease There are many different arms to this study, each one looking at separate conditions. We need to investigate the genes/genetic factors of many individuals/families with exactly the same condition. The cells in your blood carry a complete set of your genetic material (genes), which we can study. We would like to better understand the gene(s)/genetic factors that may be the cause of the condition in you/your family.

 Tumour Disorders

Posted 1 year ago by Wales Gene Park

EuroNet-PHL-C2: Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents Treatment for Hodgkin lymphoma is often very successful, and has given us high cure rates. Standard treatment is chemotherapy, and in children and young people, additional radiotherapy is sometimes needed. Unfortunately, radiotherapy can lead to long-term side effects, such as cardiovascular system disease and increased risk of secondary cancers later on in life. In this trial, researchers want to individually tailor treatment for each child and young person, effectively treating Hodgkin lymphoma, but avoiding over-treatment and thereby reducing the late side-effects. the main goal is to further reduce the use of radiotherapy, thereby avoiding the long-term side effects often seen with radiotherapy. The aim of this study is to: Reduce numbers of children needing radiotherapy and minimise the extent of irradiation Investigate if intensifying chemotherapy in children with intermediate/advanced Hodgkin lymphoma will compensate for the reduction in radiotherapy

 Classic Hodgkin lymphoma /  University Hospital of Wales

Posted 1 year ago by Wales Gene Park

The PNET 5 study has been designed for children and young people aged from 3 yrs to 22 yrs with standard risk  medulloblastoma who have undergone surgery to remove the primary tumour. The presence of biological markers of  the WNT medulloblastoma disease subgroup (mutation of the beta¬catenin gene, or presence of the beta¬catenin  protein and loss of chromosome 6) and aged  < 16 defines the patient as Low Risk biological profile. The presence of  the WNT markers and aged 16 and over, or the absence of the WNT markers defines the patient as Standard Risk  biological profile. Low risk group patients will receive reduced doses of radiotherapy (compared to previous study PNET 4) to the brain  and spine every day for 10 days, together with boost doses to the primary tumour for a further 20 days. Maintenance chemotherapy will consist of 6 cycles of Regimen A alternating with 6 cycles...

 Medulloblastoma

Posted 1 year ago by Wales Gene Park

ProMPT: Molecular mechanisms of disease progression and the development of novel treatment strategies in advanced prostate cancer (Northern Prostate Cancer Collaborative (ProMPT))

 Prostate Cancer

Posted 1 year ago by Wales Gene Park

International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy MyeChild 01 is an international phase III clinical trial in children with acute myeloid leukaemia (AML); a disease with a significant mortality. It will compare two induction chemotherapy regimens: mitoxantrone and cytarabine (current standard treatment) with liposomal daunorubicin and cytarabine. This will test liposomal daunorubicin, which is believed to be less cardiotoxic than similar conventional drugs, although this is unproven. Patients responding well to induction chemotherapy are eligible for a randomisation of two consolidation regimens: high dose cytarabine (current standard treatment) or fludarabine and cytarabine (FLA); a regimen commonly used in patients with relapsed disease, testing whether FLA is more effective in front line therapy than standard consolidation treatment. Patients with cytogenetic features associated with a higher risk of relapse and those responding...

 Acute myeloid leukaemia /  Noah's Ark Children's Hospital for Wales

Posted 1 year ago by Wales Gene Park

CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Doctors treat mesothelioma with chemotherapy. After chemotherapy if the mesothelioma comes back the aim is to control symptoms. This is called active symptom control. Researchers want to find out if nivolumab can help these people. Nivolumab is a type of immunotherapy drug called a monoclonal antibody. It works by stimulating the body’s immune system to recognise and kill cancer cells. We know from research that nivolumab could help people whose mesothelioma has come back after chemotherapy. But it isn’t known if it as good as active symptom control. In this trial most people will have nivolumab and some will have a dummy drug (placebo). The main aims of the trial are to find: how well nivolumab works for people whose mesothelioma has come back after chemotherapy how safe it...

 mesothelioma /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

PARTNER: Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or Gbrca Surgery is often used for early breast cancers. Sometimes you have chemotherapy before surgery. This is called neo adjuvant chemotherapy. It can shrink the cancer and make the surgery more successful. In this trial, researchers are looking at whether adding a drug called olaparib (also called Lynparza) improves neo adjuvant chemotherapy. Olaparib is a type of biological therapy called a PARP-1 inhibitor.  PARP is a protein that helps cells to repair. Doctors think that olaparib can stop the cancer cells from repairing themselves. In this trial, people have 1 of the following: chemotherapy chemotherapy with olaparib The chemotherapy drugs used in this trial are: paclitaxel carboplatin These are commonly used to treat breast cancer but are not routinely used to...

 BRCA1 and BRCA2 /  Wales Wide

Posted 1 year ago by Wales Gene Park

The Scotty Study: whole genome sequencing study of young colon cancer patients and their parents Scientists in Edinburgh are leading a groundbreaking UK-wide study that could help doctors and scientists identify patients at risk of developing bowel cancer and find new treatments for the disease. Professor Malcolm Dunlop and his team from the Cancer Research UK Edinburgh Centre is leading the SCOTTY study (Sequencing of COlon Trios in The Young). Funded by Cancer Research UK, the research group is studying the genetic make-up of patients who have been diagnosed with bowel cancer at a very young age. The scientists are searching for mutations in the DNA of young bowel cancer patients, to enable them to define more of the underlying genetic causes of the disease. There are around 41,700 new bowel cancer cases in the UK every year*, and every year around 16,000 people in the UK die from the...

 Colon Cancer /  Wales Wide

Posted 1 year ago by Wales Gene Park

The Genetics of Endocrine Tumours is an observational clinical trial. The study currently has 500 families and 3000 sporadic subjects recruited from almost 50 NHS sites around the country. Any patient with a pituitary tumour is eligible to enrol, though we are particularly interested in the cohort of familial isolated pituitary adenoma (FIPA) patients. FIPA accounts for around 5% of pituitary adenomas with 20% of these patients having a mutation in the gene Aryl Hydrocarbon Receptor Interacting protein (AIP). Our study has helped to characterise AIP and other novel genes that contribute to pituitary tumorigenesis. We are lucky to receive regular bloods and fresh tissue from pituitary tumour patients which are used for DNA/RNA analysis, tissue culture and in-vivo models.

 Genetics /  Cardiff University

Posted 1 year ago by Wales Gene Park

Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5- Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy (ROSCO) Doctors often give chemotherapy first to help shrink tumours before surgery for breast cancer. If you have invasive breast cancer you might be offered a combination of drugs that includes a taxane such as docetaxel (also called Taxotere). Or you might have combination that includes an anthracycline such as epirubicin. At the moment, doctors usually give both drugs one after the other. These drugs work in different ways to kill cancer cells. For some people epirubicin works well and for other people docetaxel works well. But doctors aren’t sure which drugs work best for which people. All drugs have side effects and doctors don’t want to give drugs that people don’t need. In this trial, researchers are looking at...

 Hereditary breast cancer /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum–resistant ovarian cancer Women with platinum resistant ovarian cancer (OC) have limited responses to standard therapy, and clinical trials with novel agents are therefore highly justified. Olaparib is a potent PARP inhibitor that has shown enhanced activity in women with relapsed BRCA-mutated OC in both platinum sensitive and resistant settings. Angiogenesis inhibitors, such as the oral tyrosine kinase inhibitor cediranib, are active in OC, and have shown additive effects when combined with PARP inhibitors preclinically, as hypoxia-induced downregulation of homologous recombination repair genes, BRCA1, 2 and RAD51 enhances PARP inhibitor sensitivity. Recent phase 2 trials in relapsed platinum-sensitive OC have also shown benefit from the combination of olaparib and cediranib compared to olaparib alone. The OCTOVA trial investigates the benefit of single agent olaparib compared to olaparib and cediranib or weekly paclitaxel in women...

 Familial ovarian cancer /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma. Following a stem cell transplant for myeloma, there can be no signs of the disease. This is called remission  After some time, your myeloma might come back. This is a relapse. If this happens, you can have treatment with: a targeted cancer drug (biological therapy) called thalidomide a steroid drug called dexamethasone In this trial doctors are looking at a new drug called ixazomib. Ixazomib is a targeted cancer drug called a cancer growth blocker. It blocks certain proteins that tell cancer cells to divide and grow. Everybody taking part has thalidomide, dexamethasone and ixazomib. This is re-induction treatment. Then, you might have 1 of the following: a transplant using your own stem cells...

 Multiple myeloma /  Singleton Hospital

Posted 1 year ago by Wales Gene Park

ARIEL 4: A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Globally, ovarian cancer is the eighth most common cancer and the seventh leading cause of cancer death among women. Cancer is caused by changes to genes that control the way our cells function. Chemical substances and other formulations are used in treatment. Chemotherapy is a treatment where chemical substances are used to damage and kill cancer cells. An enzyme inhibitor is a molecule that binds to an enzyme, to help slow down a reaction or to prevent unwanted change. Inhibitors are used in cancer treatments for that purpose. Rucaparib is a molecule inhibitor of enzymes. The main purpose of this study is to evaluate safety, disease status and progression-free survival of Rucaparib versus standard chemotherapy for treatment of certain ovarian, fallopian tube and primary...

 Malignant tumor of fallopian tubes /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

We propose to study a group of genetic conditions, called RAS¬MAPK pathway disorders, in which high rates of congenital abnormalities, learning difficulties, short stature and other health and developmental problems occur (including childhood tumours). The incidence of these various problems is not yet fully known in the different conditions. This study seeks to find out how common these different features are across the conditions. Changes in many different genes cause these disorders. The proteins that these genes code for all work together in a biochemical pathway, called the RAS¬MAPK pathway. We will examine what particular problems are associated with particular changes (mutations) in each of the genes. Some patients with these conditions do not currently have a known genetic reason for their condition, and we shall seek to identify new genes for these conditions. To do this, a group of patients will be studied, and blood and, where available, other...

 RAS-MAPK pathway /  Cardiff University

Posted 1 year ago by Wales Gene Park

National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer The trial consists of a series of parallel multi-centre single arm Phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective. The trial is primarily an enrichment putative biomarker design, including patients who are positive for at least on of the actionable targets included in the trial. Patients who are positive for just one putative biomarker will receive the experimental targeted drug specific for that putative biomarker. Putative biomarkers within each drug cohort have been chosen such that in the majority of cases it is not expected that patients will be positive for...

 Non-small cell lung cancer /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

PHITT: Paediatric Hepatic International Tumour Trial Liver cancer in the paediatric population is rare with an incidence approximately 1 - 1.5 million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying cirrhotic liver diseases. The ChiLTERN project builds on a unique opportunity to undertake a comprehensive research program linked to an ambitious global partnership which will see the single largest clinical trial (the Paediatric Hepatic International Tumour Trial - PHITT) ever undertaken in this population of patients, with several randomised questions in six subgroups of patients. PHITT and ChiLTERN will allow us to move towards an era of personalised therapy in which each patient will receive the correct amount of chemotherapy and will undergo the best surgical operation...

 Hepatic Cancer /  University Hospital of Wales

Posted 1 year ago by Wales Gene Park

Challenge: A Phase III Study Of The Impact Of A Physical Activity Program On Disease-Free Survival In Patients With High Risk Stage II Or Stage III Colon Cancer: A Randomised Controlled Trial CHALLENGE aims to determine whether a supervised physical activity (PA) programme in patients with high risk Stage II or Stage III colon cancer will improve 3- year disease-free survival (DFS) in comparison to standard care. The impact on patient-reported outcome measures (PROMS) and quality of life will also be assessed. There is compelling observational data that PA is associated with colon cancer incidence, recurrence, survival, and quality of life. The trial arms are: Intervention: A 36 month structured physical activity programme comprising supervised physical activity sessions and behaviour support sessions and provision of general health education materials (on diet and exercise). Standard Care: Provision of general health education materials on diet and exercise only.

 Rare Non-specific /  Velindre Cancer Centre

Posted 1 year ago by Wales Gene Park

Relapse (the chance of disease coming back after treatment) is very high in acute myeloid leukaemia even after  curative approaches with intensive chemotherapy and bone marrow transplantation. The bone marrow  microenvironment which includes the stromal cells (MSC) surrounding the blood cells/leukaemia cells is thought to  be a key player in chemotherapy resistance and acts as a sanctuary site for minimal residual disease (MRD) from  which relapse may occur. Once MRD is detectable, frank relapse is likely within a short time-frame affording  insufficient time for effective salvage interventions. In addition, a large proportion of patients there is no informative  MRD marker thus disease relapse can occur with little warning. In this study, we aim to investigate the role of patient  MSC in protecting AML cells at different stages of treatment including post chemotherapy and after stem cell  transplantation. By developing a 3D dynamic model of leukaemia-stroma interactions which can better mimic...

 Acute myeloid leukaemia /  Cardiff University

Posted 1 year ago by Wales Gene Park

A trial comparing surgery, conventional radiotherapy and stereotactic radiotherapy for localised prostate cancer (PACE) If prostate cancer is diagnosed before it has spread outside the prostate gland, there are several treatment options including surgery to remove the prostate gland, external radiotherapy and internal radiotherapy (brachytherapy). Some men may now also be offered a new way of having external radiotherapy called stereotactic radiotherapy. You have stereotactic radiotherapy over a shorter period of time than conventional radiotherapy. All of the treatments listed above work well, but doctors don’t know if one is better than the other or which one has the fewest side effects. In this trial, some men will have keyhole surgery to remove the prostate gland (laparoscopic prostatectomy), some will have conventional radiotherapy and some will have stereotactic radiotherapy. The aim of the study is to compare the different treatments to find out How long men live after each treatment...

 Prostate Cancer /  Wales Wide

Posted 1 year ago by Wales Gene Park

National Study of Colorectal Cancer Genetics There are several different factors that can increase risk of developing bowel (colorectal) cancer. One is an inherited faulty gene (genetic mutation). An inherited genetic mutation may mean that several people in the same family develop bowel cancer. This is called a strong family history’. Inherited conditions such as familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC) also increase risk. The increase in risk will depend on which gene is damaged, or even on which part of the gene is damaged. Some genetic mutations are ‘high penetrance’ and increase risk a lot. Others are ‘low penetrance’ and don’t increase risk very much. The aim of this study is to find out more about high penetrance genes, and how much they increase risk. And to look for new low penetrance genes.

 Rare Non-specific /  Wales Wide

Posted 1 year ago by Wales Gene Park

Researchers want to know more about people who have mesothelioma, their symptoms and how it affects their life. Mesothelioma of the lung is difficult to treat. Researchers are looking for better treatments and how to improve care for people with mesothelioma. In this study they will collect information about: your quality of life any symptoms you have They will also collect medical information including: blood samples any tests you might have Mesothelioma can cause fluid to build up between the sheets of tissue that surround your lung. Treatment for this is to drain the fluid off. The researchers also want to collect samples of this fluid. The team will use this information to: find out more about mesothelioma improve the care for people with mesothelioma

 mesothelioma /  Wales Wide

Posted 1 year ago by Wales Gene Park

The role of routine and novel biomarkers and their correlation with clinical outcome measures in patients undergoing surgical interventions for benign and malignant disorders of the prostate and bladder.

 Penile Cancer /  Wrexham

Posted 1 year ago by Wales Gene Park

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) (InPACT) Penis cancer is a rare disease with a limited body of evidence on which to base the majority of management decisions. In 2011, 558 new cases of penis cancer were registered. Spread to lymph nodes in the groins and the pelvis is the most important prognostic factor: around 80% of patients who have a single involved lymph node in the groin will be alive at 5 years, but only 10% of patients who have involved deeper pelvic lymph nodes will survive. Conventional treatment for patients with positive groin nodes is surgery to remove all the affected nodes. Chemotherapy (CT) given before surgery (neoadjuvant CT) is shown to shrink affected nodes, but the impact of this approach on survival has not been assessed. Use of synchronous chemoRT (radiotherapy given at the same time as CT) has traditionally been in two...

 Penile Cancer /  Wales Wide

Posted 1 year ago by Wales Gene Park

EMBRACE: Epidemiological study of BRCA1 and BRCA2 mutation carriers This study collects information about people who have inherited faulty breast cancer genes. A small number of men and women have inherited faulty genes which means that they at an increased risk of developing certain cancers. Two of these genes are called BRCA1 and BRCA2. When someone has a fault in these genes they are more likely to develop cancers of the breast, ovary or prostate. The EMBRACE study, which stands for Epidemiological Study of Familial Breast Cancer, aims to create a register of families who have a fault in these genes. The people taking part will be asked to fill in a questionnaire and to give a small sample of blood, which will be looked at in a laboratory. With this information they hope to find out How many people go on to develop cancer What other factors may play a part...

 BRCA1 and BRCA2 /  Cardiff


No post found